Drug intelligence / Profile preview

paracetamol + metamizole

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

Paracetamol + metamizole is a non-opioid analgesic and antipyretic combination, used for the management of moderate to severe pain and fever. Paracetamol (also known as acetaminophen) acts primarily by inhibiting prostaglandin synthesis in the central nervous system, leading to reduced pain and fever. Metamizole (also known as dipyrone) is a pyrazolone derivative with potent analgesic, antipyretic, and spasmolytic properties; its mechanism involves inhibition of prostaglandin synthesis via cyclooxygenase blockade and possible effects on endogenous opioid systems. The combination may be used when monotherapy is insufficient or when additive/synergistic effects are desired, though evidence suggests no significant synergistic benefit over standard regimens[2]. Both drugs are available in oral and injectable forms individually; fixed-dose combinations may exist in some markets but are not globally standardized.

Brand names
No unique global brand name for the fixed combination; individual components are marketed under various names (see comments).
Other names
acetaminophen + dipyroneacetaminophen + metamizoleparacetamol + dipyrone
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)COX-3 (Mitochondrially encoded cytochrome c oxidase subunit 3)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on paracetamol + metamizole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paracetamol + metamizole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call